ZA202003097B - Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof - Google Patents

Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof

Info

Publication number
ZA202003097B
ZA202003097B ZA2020/03097A ZA202003097A ZA202003097B ZA 202003097 B ZA202003097 B ZA 202003097B ZA 2020/03097 A ZA2020/03097 A ZA 2020/03097A ZA 202003097 A ZA202003097 A ZA 202003097A ZA 202003097 B ZA202003097 B ZA 202003097B
Authority
ZA
South Africa
Prior art keywords
delta
methods
compositions
cell populations
selective expansion
Prior art date
Application number
ZA2020/03097A
Other languages
English (en)
Inventor
Jakobovits Aya
Kadyl Satpayev Daulet
Foord Orit
Frank Jing Yifeng
Shao Hui
Michael Romero Jason
Michael Brodey Mary
Ian Hoopes Matthew
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of ZA202003097B publication Critical patent/ZA202003097B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA2020/03097A 2017-11-15 2020-05-25 Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof ZA202003097B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586782P 2017-11-15 2017-11-15
PCT/US2018/061384 WO2019099744A1 (en) 2017-11-15 2018-11-15 METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
ZA202003097B true ZA202003097B (en) 2025-09-25

Family

ID=64755702

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/03097A ZA202003097B (en) 2017-11-15 2020-05-25 Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof

Country Status (12)

Country Link
US (1) US12221480B2 (enExample)
EP (1) EP3710472A1 (enExample)
JP (1) JP2021502816A (enExample)
KR (1) KR20200098518A (enExample)
CN (1) CN111801349A (enExample)
AU (1) AU2018370120C1 (enExample)
CA (1) CA3082818A1 (enExample)
IL (1) IL274640B1 (enExample)
MX (1) MX2020005005A (enExample)
SG (1) SG11202004506WA (enExample)
WO (1) WO2019099744A1 (enExample)
ZA (1) ZA202003097B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126896A1 (en) 2018-12-03 2020-06-11 Adicet Bio Inc. Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof
US20220154144A1 (en) * 2019-04-26 2022-05-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
IL293459A (en) * 2019-12-03 2022-07-01 Adicet Bio Inc Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof
CA3235971A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US5185250A (en) 1986-07-03 1993-02-09 T Cell Sciences, Inc. Human γ, δT cell antigen receptor polypeptides and nucleic acids
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
WO2000078348A1 (en) 1999-06-17 2000-12-28 University Of Vermont And State Agricultural College Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
WO2001022816A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
CN1306027C (zh) 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
US20060205089A1 (en) 2003-04-14 2006-09-14 Montana State University Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
US7340913B2 (en) 2004-08-05 2008-03-11 Manitowoc Foodservice Companies, Inc. Ice machine and ice-making assembly including a water distributor
US20080026986A1 (en) 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
CA2735193A1 (en) 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
PH12012501491B1 (en) 2010-01-22 2019-06-28 Dow Agrosciences Llc Targeted genomic alteration
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
EP2684600A1 (en) 2012-07-10 2014-01-15 Laboratoires Meiners Sarl Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes
US20150259645A1 (en) 2012-11-08 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale Method for inducing il-2-free proliferation of gamma delta t cells
CN102994448A (zh) 2012-12-13 2013-03-27 上海柯莱逊生物技术有限公司 一种体外扩增γδT细胞的方法
US9393257B2 (en) 2013-03-01 2016-07-19 Regents Of The University Of Minnesota TALEN-based gene correction
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
KR102601469B1 (ko) 2014-04-10 2023-11-14 라바 테라퓨틱스 엔.브이. 인간 Vγ9Vδ2 T 세포에 결합하는 면역글로불린
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
CA2988050A1 (en) * 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF

Also Published As

Publication number Publication date
SG11202004506WA (en) 2020-06-29
KR20200098518A (ko) 2020-08-20
JP2021502816A (ja) 2021-02-04
AU2018370120A1 (en) 2020-06-25
IL274640B1 (en) 2025-10-01
US20230257462A1 (en) 2023-08-17
IL274640A (en) 2020-06-30
EP3710472A1 (en) 2020-09-23
AU2018370120B2 (en) 2023-11-09
MX2020005005A (es) 2020-08-27
AU2018370120C1 (en) 2024-05-30
CA3082818A1 (en) 2019-05-23
CN111801349A (zh) 2020-10-20
US12221480B2 (en) 2025-02-11
WO2019099744A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
ZA202003097B (en) Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof
EA202190365A1 (ru) Способы изготовления пакетов-мессенджеров растений
MX2021006786A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
MY195110A (en) Antibodies to PD-1 and uses Thereof
MY191649A (en) Antibodies to tigit
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
MX2019007020A (es) Anticuerpos il-11.
MY194184A (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
PH12020500667A1 (en) Multispecific antibodies and use thereof
MA52894A (fr) 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci
IL319114A (en) Expansion of gamma delta T cells, compositions and methods for use thereof
MX2019007021A (es) Anticuerpos il-11ra.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2020008022A (es) Composiciones para uso en operaciones de petroleo y gas.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
PH12018500295B1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
PH12016501680A1 (en) Anti-egfrviii antibodies and uses thereof
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
SA520412283B1 (ar) Cd22 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ
MY205689A (en) Antibody molecules to cd138 and uses thereof
MX2021001703A (es) Polipeptidos de union a ox40 y sus usos.